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Several neutralizing sites of the human papillomavirus (HPV) capsid are known to be critically dependent on the conforma-
tion of the capsid. However, efficient production of HPV16 capsids in mammalian cells has been difficult, possibly because
the HPV genome contains negative regulatory elements. To circumvent these problems, we cloned the HPV16 L1 and L2
genes from a healthy HPV16-infected woman into a Semliki Forest virus based expression vector (P. Liljestro¨m and H.
Garoff, Biotechnology 9, 1356–1361, 1991). Recombinant HPV16 L1- or L2-producing Semliki Forest virus was generated
and used for infection of mammalian cells. The HPV16 L1 and L2 proteins were efficiently expressed and the majority of
the L1 protein self assembled into virus-like particles (VLPs). Coexpression of L1 and L2 resulted in incorporation of L2
into the VLPs. The particles had a density of 1.3 g/ml as determined by density gradient centrifugation. Transmission
electron microscopy revealed that the particles had a morphology similar to native virions. The HPV16 VLPs produced by
the Semliki Forest virus expression system may be useful as a conformationally correctly assembled target for studies of
HPV attachment, assembly, serology, or vaccination. q 1995 Academic Press, Inc.
INTRODUCTION cules, whereas the location of L2 is still unknown (Baker
et al., 1991). The L1 protein may, if expressed in eucaryotic
The oncogenic types of human papillomaviruses cells, selfassemble into virus-like particles (VLPs), which
(HPVs) are associated with anogenital cancers (zur Hau- resemble the native virus particles but lack the viral ge-
sen, 1991). Infection with high risk HPV types, in particu- nome. VLPs have been generated by expression of the
lar HPV16, is the most important cause of cervical cancer structural proteins of HPV1, HPV16, and bovine papillo-
precursor lesions. Since HPV16 is found in about 60% of mavirus (BPV) in vaccinia virus-based expression systems
cervical cancers, development of a preventive vaccine (Hagensee et al., 1993; Zhou et al., 1993, 1991), by expres-
against HPV16 is likely to be important for cancer preven- sion of HPV11, 16, 33, and BPV structural proteins in insect
tion (Dillner, 1992). However, efficient production of cells from recombinant baculovirus (Kirnbauer et al., 1992,
HPV16 capsids in mammalian cells has been difficult, 1993; Rose et al., 1993; Volpers et al., 1994) and by expres-
possibly because of the existence of negative regulatory sion of HPV6 and 16 in fission yeast Schizosaccharomyces
elements on late HPV mRNAs that code for the capsid pombe (Sasagawa et al., 1995). However, the HPV16 L1
proteins (Kennedy et al., 1991; Tan et al., 1995; Tan and protein of the HPV16 reference strain (Seedorf et al., 1985)
Schwartz, 1995). Therefore, large-scale preparation of vi- did not selfassemble into VLPs when produced from re-
rions has not been possible, although some HPV types combinant vaccinia virus (Zhou et al., 1991). Preparative
have been propagated by xenografting HPV-containing amounts of HPV16 VLPs could be produced when a wild-
tissue (Kreider et al., 1987) or HPV-containing cell lines type clone of HPV16 L1 was used to produce L1 protein
(Sterling et al., 1990). Latently HPV-infected keratinocytes in a baculovirus expression system (Kirnbauer et al., 1992).
induced to differentiate in organotypic (raft) cultures have However, it has been shown that posttranslational pro-
also been shown to produce virions (Dollard et al., 1992; cessing of proteins in insect cells differs greatly from pro-
Meyers et al., 1992). The limited amounts of virions pro- tein processing in mammalian cells (Moore et al., 1990).
duced in these systems are not suitable as candidates In this paper we report the expression of HPV16 L1- and
for preventive vaccines, since they contain the oncogenic L2-containing VLPs in mammalian cells using a Semliki
viral DNA. Forest virus (SFV)-based expression system (Liljestro¨m
The native HPV particle is nonenveloped and has an and Garoff, 1991). This system has several advantages.
icosahedral symmetry composed of 72 pentameric capso- First, SFV has a broad host range which would allow
meres. Each capsomere is composed of L1 protein mole- expression of L1 and L2 in mammalian cells of various
origins. Second, SFV replicates in the cytoplasm which
allows bypassing of nuclear regulatory factors that may1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 468 331 399. E-mail: Stefan.Schwartz@mtc.ki.se. decrease expression levels.
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MATERIALS AND METHODS Generation of HPV 16 L1 recombinant virus and
infections
Recombinant plasmids and sequencing
For production of recombinant SFV, capped RNA tran-
scribed from pSFV16L1, pSFV16L2 or pSFV3-lacZ wasThe HPV16 L1 or L2 coding sequences were PCR-
electroporated into BHK-21 cells together with an equalamplified from a HPV16 positive cervical swab sample
amount of RNA produced from the helper plasmidusing primers L1START (5*-CAGCGCGCCAAGATGTCT-
pSFV-Helper1. Medium containing recombinant SFVCTTTGGCTGCCTAG-3* ) and L1STOP (5*-CACTCGAGC-
(vSFV16L1, vSFV16L2, or vSFV3-lacZ) was harvested 24TTACAGCTTACGTTTTTTG-3* ) or L2START (5*-CAGCGC-
to 48 hr posttransfection and was used for infections ofG C C C T T A A C A A T G C G A C A C A A A C G-3* ) and
BHK-21 cells directly or was stored at 0707 until use.L2STOP (5*-CAGTCGACCGTGGCCTCACTAGGCAGCC-
For infection of BHK-21 cells, recombinant virus was3* ), respectively. The amplified fragments were first li-
first diluted 1:10 in minimal essential medium (MEM)gated blunt end into EcoRV-digested and calf intestinal
containing 0.2% bovine serum albumin, 2 mM glutamine,alkaline phosphatase (CIAP)-treated pBluescript (Stra-
and 20 mM HEPES. A total volume of 500 ml of virustagene), resulting in pT7L1 and pT7L2. The L1 coding
suspension was used to infect a 35-mm plate with cells.sequence was subsequently transferred into the SmaI-
After 60 min, virus containing medium was removed anddigested, CIAP-treated SFV expression vector, pSFV1
3 ml of BHK-21 medium was added to each plate and(Liljestro¨m and Garoff, 1991) (kindly provided by H. Garoff
incubation was continued for 24 to 48 hr.and P. Liljestro¨m), resulting in plasmid pSFV16L1. To
generate pSFV16L2, the two SpeI restriction sites in the
Western immunoblotting and seraHPV16 L2 coding sequence were first destroyed by site-
directed mutagenesis on uracil containing single-strand Twenty-four to forty-eight hours posttransfection or
DNA of plasmid pT7L2, as described (Luukkonen et al., postinfection cells were harvested in 500 ml of lysis buffer
1995). These mutations did not affect the protein se- (0.5% Triton X-100, 100 mM Tris–HCl (pH 7.5) or 0.2%
quence of L2. The mutated L2 coding sequence was Triton X-100, 1% SDS, and 100 mM Tris–HCl (pH 7.5))
transferred into SmaI-restricted pSFV1, resulting in and freeze-thawed three times. Cell lysates were cleared
pSFV16L2. pSFV3-lacZ and pSFV-Helper1 were provided of insoluble material by centrifugation at 12,000 g for 15
by H. Garoff and P. Liljestro¨m and have been described min. Fractions obtained after CsCl gradient centrifugation
(Liljestro¨m and Garoff, 1991). were adjusted to 0.5% Triton X-100 and 100 mM Tris–
Sequencing of HPV16 L1 was performed using oligonu- HCl (pH 7.5). Proteins were electrophoretically separated
cleotides 16–823 (5*-TTATACATTAAAGGCTCTGGGTC-3*) on 12% polyacrylamide–SDS gels and transferred onto
and 16 – 490 (5*-CCTATAGGGGAACACTGGG-3* ) and nitrocellulose membranes by electroblotting in transfer
HPV16 L2 was partially sequenced using oligonucleotide buffer (25 mM Tris, 190 mM glycine, 20% methanol) at
L2M1 (5*-GCATCAATAAAGCTTGTTTCTTCCAC-3* ). constant current (250 mA) for 12 to 16 hr. Membranes
were blocked for 1 hr at 377 with 10% nonfat milk in PBS
containing 0.3% Tween 20 (PBS-T). After washing three
RNA synthesis and transfection times in PBS-T buffer, the blots were incubated for 1 hr
at 377 with the rabbit HPV16 L1 peptide antiserum 16a
Plasmid pSFV16L1, pSFV16L2, pSFV3-lacZ, and pSFV- (1:1,000 dilution) (Dillner et al., 1991) or with a pool of
Helper1 were linearized with SpeI and capped RNA was guinea pig HPV16 L2 antisera against peptides L2:44,
synthesized in vitro at 377 for 1 hr in a total volume of 50 L2:46, and L2:60 (the pool of the sera was diluted 1:500)
ml containing SP6 buffer (40 mM HEPES–KOH (pH 7.4), (Heino et al., 1995), washed in PBS-T, and incubated with
6 mM MgOAc, 2 mM spermidine–HCl), 5 mM DTT, 1 mM horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
m7(G5* )ppp(5* )G, 0.5 mM GTP, 1 mM CTP, 1 mM UTP, (Amersham) or with HRP-conjugated anti-guinea pig im-
1 mM ATP, 50 U RNasin, and 30 U SP6 RNA polymerase. munoglobulins (Dako) diluted 1:10,000 in PBS-T buffer.
Baby hamster kidney-21 (BHK-21) cells were trypsinized Specific proteins were visualized using the enhanced
and washed once with PBS. Twenty to twenty-five microli- chemiluminescence (ECL) detection system (Amer-
ters of each recombinant RNA was used to electroporate sham).
8 1 106 cells. The cells were pulsed twice at 850 V/
25 mF at room temperature. The transfected cells were Radioimmunoprecipitation
resuspended in 24 ml of BHK-21 medium (BRL) con-
taining 5% fetal calf serum, 10% tryptose phosphate broth, Transfected cells were washed twice with prewarmed
20 mM HEPES, 2 mM glutamine, 0.1 U/ml penicillin, 0.1 PBS and then twice with methionine (Met)-free 11 MEM.
mg/ml streptomycin, and plated onto eight 35-mm cell The cells were starved for 30 min at 377 in 1.0 ml of Met-
culture plates. Cells were harvested 24 to 48 hr post- free medium containing 0.5% FCS followed by metabolic
labelling for 1 to 4 hr with 200 mCi of (35S)-Met (Amersham).transfection.
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The cells were washed with ice-cold PBS, scraped off the g for 5 min, washed once with ice-cold PBS, and stored
at 0707. Thawed cell pellets were resuspended in 10 mlplastic, and pelleted by centrifugation followed by lysis in
500 ml SDS–lysis buffer (100 mM Tris–HCl (pH 7.5), 0.2% of ice-cold PBS and were sonicated on ice 31 30 sec
with a Soniprep 150. The lysates were layered on 40%Triton X-100, and 1% SDS). For separation of nuclear and
cytoplasmic fractions, cells were first lysed in lysis buffer (wt/vol) sucrose–PBS cushions and centrifuged for 2.5
hr at 25,000 rpm in a SW-28 rotor. The pellets were resus-(10 mM Tris–HCl (pH 7.5), 0.14 M NaCl, 5 mM KCl, and
1% NP-40) followed by low speed centrifugation at 8,000 g pended in 8 ml of PBS containing 27% (wt/wt) CsCl,
moved into quick-seal tubes, and centrifuged in SW28for 2 min. Nuclear fractions were washed once with lysis
buffer and the pellets were resuspended in lysis buffer rotor for 20 to 22 hr at 28,000 rpm. Fractions were col-
lected from each CsCl gradient and the density of thewithout NP-40. An equal volume of lysis buffer containing
1% SDS was added and the samples were incubated on various fractions was determined by refractometry. The
samples were then dialyzed against PBS over night.ice for 10 min, followed by freezing on dry ice. The samples
were thawed at room temperature and centrifuged for 2 For transmission electron microscopy, selected fractions
were adsorbed onto formvar-coated grids with thin carbonmin at 8,000 g. The supernatants were mixed with preim-
mune rabbit serum (1:100 dilution) and incubated at 47 for 1 films and stained with 2% phosphotungstic acid. The sam-
ples were examined with a Philips PW 6006 transmissionhr followed by addition of protein A-Sepharose (Pharmacia)
suspension and incubated at 47 for 30 min. Samples were electron microscope at a 75,000–100,0001 magnification.
centrifuged and supernatants from each sample were col-
lected and aliquoted into two eppendorf tubes, to which RESULTS
either preimmune rabbit serum, rabbit HPV16 L1 peptide
Production of HPV16 L1 and L2 using a Semliki
antiserum 16a (1:100 dilutions) (Dillner et al., 1991), preim-
Forest virus-based eucaryotic expression system
mune guinea pig serum, or a pool of guinea pig HPV16 L2
peptide antisera against peptides L2:44, L2:46, and L2:60 We investigated if the HPV16 L1 and L2 proteins could
be produced in mammalian cells using a SFV-based ex-(1:20 dilution of the pool) (Heino et al., 1995) was added.
Incubation was at 47 for 12 to 16 hr with gentle rocking. pression system (Liljestro¨m and Garoff, 1991). The L1
and L2 coding sequences were first PCR-amplified fromProtein A–Sepharose was added and samples were incu-
bated for 3 hr at 47. The Sepharose beads were washed high molecular weight DNA prepared from a HPV16 posi-
tive cervical swab sample obtained from a healthy Swed-three times in RIPA buffer (25 mM Tris–HCl (pH 7.4), 75
mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, ish woman and cloned into the SFV vector pSFV1 (Lilje-
stro¨m and Garoff, 1991) as described under Materialsand 0.05% SDS) and resuspended in 51 SDS-loading buffer
(625 mM Tris (pH 6.8), 6.25% SDS, 50% glycerol, and 20% and Methods. These cloning steps resulted in pSFV16L1
and pSFV16L2 (Fig. 1A). Capped RNA transcribed in vitro2-mercaptoethanol), boiled, and loaded on 10% polyacryl-
amide–SDS gels under reducing conditions. Immunopre- from the SP6 promoter on pSFV16L1 or pSFV16L2 (Fig.
1A) was transfected into BHK-21 cells by electroporation.cipitated proteins were visualized by autoradiography (Ko-
dak XAR film) at 0707. Immunoprecipitation of VLPs was Parallel transfections were performed with RNA gener-
ated from the control plasmid pSFV3-lacZ (Fig. 1A) (Lilje-performed in 11 RIPA buffer.
stro¨m and Garoff, 1991). Production of HPV16 L1 or L2
Immunofluorescence proteins in transfected cells was assessed by radioim-
munoprecipitation with rabbit anti HPV16 L1 peptide anti-
For immunofluorescence, transfected, or infected cells
serum (Dillner et al., 1991) or a pool of guinea pig anti-
were plated onto glass slides. The cells were rinsed with
HPV16 L2 peptide antisera (Heino et al., 1995), as de-
PBS, fixed in methanol at 0207, and washed again with
scribed under Materials and Methods. High levels of L1
PBS. Rabbit anti-L1 peptide antiserum 16a diluted 1:20 in
or L2 proteins were detected in cells transfected with
PBS (Dillner et al., 1991) or guinea pig antiserum against
RNA from pSFV16L1 or pSFV16L2, respectively (Fig. 1B).
HPV16 L2 peptide L2:46 diluted 1:20 (Heino et al., 1995)
These bands were not detected in cells transfected with
was applied to the fixed cells that were incubated for 60
RNA generated from the control plasmid pSFV3-lacZ (Fig.
min in a moist chamber at 377. For detection of L2, the
1B), nor in untransfected cells (data not shown).
cells were incubated with rabbit immunoglobulins to
To confirm the identity of the cloned genes, they were
guinea pig immunoglobulins (Dako) diluted 1:20 in PBS
partially sequenced. A segment from the HPV16 L1 cod-
before fluorescein-conjugated swine anti-rabbit Ig (Dako)
ing region between nt 6506 and nt 6623, which allows
diluted 1:20 in PBS was added. Finally the cells were
discrimination between the closely related HPV types in
washed with PBS and mounted with a coverslip.
phylogenetic group A (Chan et al., 1992; Myers et al.,
1994), was sequenced to confirm that the amplificationPurification of VLPs and electron microscopy
product was derived from HPV16. In addition, sequence
variation between different HPV16 variants has been ob-Cells were harvested 24 to 48 hr postinfection by
scraping with a rubber policeman and centrifuged at 600 served in this region (Chan et al., 1992; Icenogle et al.,
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FIG. 1. Expression of HPV16 L1 and L2 using a SFV-based expression system. (A) Schematic structures of plasmids pSFV16L1, pSFV16L2, pSFV3-
lacZ, and pSFV-Helper1. Black bars indicate promoter sequences, stippled bars SFV sequences, and open bars HPV16 or lacZ coding sequences,
as indicated. The location of the SpeI restriction site used for linearization of the plasmids prior to RNA synthesis from the SP6 promoter is indicated.
(B) Immunoprecipitation of L1 and L2 from radiolabeled cells transfected with capped RNA, rSFV16L1, rSFV16L2, or rSFV3-lacZ produced from
plasmids pSFV16L1, pSFV16L2, and pSFV3-lacZ, respectively. L1, rabbit anti HPV16 L1 peptide antiserum; L2, guinea pig anti HPV16 L2 peptide
antisera; P, preimmune serum. MW, molecular weight marker. (C) Radioimmunoprecipitation of HPV16 L1 produced from cells infected with the
recombinant SFV, vSFV16L1 (left panel). Western immunoblotting with a pool of guinea pig anti HPV16 L2 peptide antisera on cell extracts from
cells infected with recombinant SFV vSFV16L2 or vSFV3-lacZ (right panel). L1, rabbit anti HPV16 L1 peptide antiserum; P, preimmune serum.
1991; Pushko et al., 1994). At variable positions 6558 (Seedorf et al., 1985) by a silent change of an A to G at nt
position 6275. The sequence between nt 4290 and nt 4540(Chan et al., 1992; Icenogle et al., 1991), 6567 (Icenogle
et al., 1991), 6582 (Icenogle et al., 1991), 6616 (Pushko in the L2 gene was also determined to confirm the origin
of the cloned HPV16 L2 gene. A silent change of G to A atet al., 1994), we found C, T, A, and A, respectively, as in
the reference strain (Seedorf et al., 1985). amino acid position 4459 and a nucleotide change of A to
T at nt 4363, resulting in a conservative change of glutamicWhereas the reference strain of HPV16 (Seedorf et al.,
1985), cloned from cervical cancer, encodes a histidine at acid to aspartic acid, was found in our clone when com-
pared to the reference strain (Seedorf et al., 1985). Theamino acid position 202 in the L1 gene, efficiently assem-
bling wild-type strains of HPV16 contain aspartic acid in same amino acid change in the HPV16 L2 sequence has
been described before (Myers et al., 1994).this position (Kirnbauer et al., 1992). For this reason, we
determined the sequence between nt 6169 and nt 6287 in
Generation of recombinant SFV producing HPV16 L1the L1 gene cloned here. We found that our clone encoded
or L2aspartic acid at amino acid position 202, and therefore had
the potential to self assemble into VLPs. In addition, we The SFV expression system is provided with a packag-
ing-deficient helper plasmid, pSFV-Helper1 (Liljestro¨mfound that our clone differed from the reference strain
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and Garoff, 1991) (Fig. 1A), which produces the structural gation. Ten fractions were collected and analyzed by
Western immunoblotting with rabbit anti-HPV16 L1 pep-proteins of SFV. When these proteins are produced in
the same cells as RNA from pSFV1-derived plasmids, the tide antiserum. The majority of the L1 proteins were
found in fraction 5 (Fig. 4A). Density determination of therecombinant RNA is packaged into SFV particles that can
be used for large scale infection of various mammalian various fractions by refractometry revealed that fraction
5 had a density of 1.3 g/ml (Fig. 4B). This is incells (Liljestro¨m and Garoff, 1991). Capped RNA pro-
duced from pSFV16L1, pSFV16L2, or pSFV3-lacZ (Fig. agreement with previous estimates of empty HPV particle
densities (Baker et al., 1991). L1 protein could also be1A) was cotransfected with capped RNA produced from
pSFV-Helper1 (Fig. 1A). Medium containing recombinant detected in the last fraction of the gradient (Fig. 4A). This
fraction probably contained free L1 protein not incorpo-SFV virus (vSFV16L1, vSFV16L2, or vSFV3-lacZ) was har-
vested and was used for infection of BHK-21 cells as rated into virus-like structures.
The assembly of L1 protein into VLPs was also exam-described under Materials and Methods. Infected cells
were harvested 24 to 48 hr postinfection and L1 or L2 ined by transmission electron microscopy. Material from
L1-positive and -negative CsCl gradient fractions wasproduction was assessed by radioimmunoprecipitation
or Western immunoblotting. The results revealed that L1 subjected to negative staining for electron microscopic
examination. Circular structures with a diameter of 50–was specifically detected in vSFV16L1-infected cells (Fig.
1C, left panel) and L2 was specifically detected in 55 nm and displaying regularly arranged capsomeres
were detected in L1 positive fractions (Fig. 5A) but notvSFV16L2-infected cells (Fig. 1C, right panel). These pro-
teins were not detected in vSFV3-lacZ-infected cells (Fig. in L1 negative samples. Therefore, HPV16 L1 produced
from recombinant SFV, vSFV16L1, assembled into VLPs1C, right panel, and data not shown). We concluded that
the recombinant Semliki Forest viruses vSFV16L1 and with predicted morphology.
vSFV16L2 efficiently produced the HPV16 L1 or L2 pro-
HPV16 L2 is incorporated into the VLPsteins upon infection of BHK-21 cells.
We next wished to determine if coinfection of BHK-
HPV16 L1 and L2 produced from recombinant SFV 21 cells with vSFV16L1 and vSFV16L2 would result in
are localized primarily in the nucleus production of VLPs containing both L1 and L2. Therefore,
large scale infections of cells with equal amounts of
To investigate if HPV16 L1 and L2 proteins produced vSFV16L1 and vSFV16L2 were performed and VLPs were
in cells infected with vSFV16L1 or vSFV16L2 were tar- purified over CsCl as described above. Seven fractions
geted to the nucleus, immunofluorescence was per- were collected and analyzed by Western immunoblotting
formed on infected cells. The results showed a clear using either L1- or L2-specific antiserum. The results
nuclear staining for both L1 and L2, demonstrating that revealed that L2 protein could be detected in all fractions
these proteins were localized primarily in the nucleus of and that the majority of L2 was found in fraction number
the vSFV16L1- or vSFV16L2-infected cells (Figs. 2A and 3 (Fig. 6A, upper panel). This fraction also harbored the
2C). Cells stained with preimmune rabbit serum or preim- majority of the L1 molecules (Fig. 6A, lower panel) and
mune guinea pig serum did not show positive staining had a density of 1.3 g/ml, as expected for the VLPs. To
(Figs. 2B and 2D). determine if L2 was indeed incorporated into the VLPs,
To confirm these results, cells infected with vSFV16L1 fraction number 3 was first subjected to immunoprecipi-
or vSFV16L2 were separated into nuclear and cyto- tation with rabbit preimmune serum or with the rabbit
plasmic fractions. Fractions of vSFV16L1-infected cells anti HPV16 L1 peptide antiserum 16a. The precipitated
were subjected to radioimmunoprecipitation with HPV16 proteins were separated on 12% SDS–polyacrylamide
L1-specific sera, while fractions of vSFV16L2-infected gels followed by immunoblotting with L2-specific antise-
cells were analyzed by Western immunoblotting with rum. The results revealed that L2 protein could be de-
HPV16 L2-specific sera. The results revealed that the tected in samples precipitated with L1 antiserum but not
majority of the L1 and L2 proteins were found in the in samples precipitated with preimmune serum (Fig. 6B),
nuclear-enriched fractions (Figs. 3A and 3B), confirming demonstrating that L1 and L2 in fraction 3 were strongly
that L1 and L2 accumulated in the nucleus. associated. We concluded that L2 was incorporated into
the VLPs. Production of VLPs in cells infected with both
HPV16 L1 produced from recombinant SFV
vSFV16L1 and vSFV16L2 was also studied by electron
assembles into virus-like particles
microscopy. VLPs found in fractions with a density of
1.3 g/ml had morphology and size similar to native HPVWe next wished to determine if L1 protein produced
virions (Fig. 5B).from the recombinant Semliki Forest virus vSFV16L1
could selfassemble into VLPs. For this purpose, BHK-21
DISCUSSIONcells in five 225-cm2 flasks were infected with vSFV16L1.
Cell extracts were prepared as described under Materi- We have shown that HPV16 capsid proteins produced
in mammalian cells using a SFV-based expression sys-als and Methods and subjected to CsCl gradient centrifu-
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FIG. 2. Localization of HPV16 L1 and L2. vSFV16L1 (A, B) or vSFV16L2 (C, D) infected BHK-21 cells were fixed in methanol and subjected to
immunofluorescence with (A) rabbit anti HPV16 L1 peptide antiserum, (B) rabbit preimmune serum, (C) guinea pig anti HPV16 L2 peptide antiserum,
or (D) guinea pig preimmune serum.
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FIG. 2—Continued
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demonstrated that HPV16 L1 produced in fission yeast
assembled into VLPs (Sasagawa et al., 1995). In contrast
to the results obtained here, which showed that L2 is
incorporated into VLPs, L2 produced in yeast was not
included in the VLP (Sasagawa et al., 1995). This again
argues that production of HPV16 L1 and L2 in mammalian
cells may be a prerequisite for correct processing and
assembly of the capsid proteins. Some investigators ob-
served that coexpression of L1 and L2 resulted in signifi-
cantly higher yields of VLPs (Hagensee et al., 1993), whileFIG. 3. HPV16 L1 and L2 proteins accumulate in the nucleus. (A) BHK-
21 cells infected with recombinant SFV, vSFV16L1, were metabolically others found a more modest increase in the number of
labeled and fractionated into nuclear and cytoplasmic fractions. The VLPs in the presence of L2 (Kirnbauer et al., 1993). We
fractions were subjected to immunoprecipitation with rabbit preimmune did not obtain substantially higher yields of VLPs when
serum (P) or with rabbit anti HPV16 L1 peptide antiserum (L1). (B) BHK-
L1 was produced in the presence of L2, which is in21 cells infected with recombinant SFV, vSFV16L2, were separated into
agreement with the results presented by Volpers et al.nuclear and cytoplasmic fractions and analyzed by Western immu-
noblotting with a pool of guinea pig anti HPV16 L2 peptide antisera. (1994) on HPV33 VLPs.
N, nuclear fraction; C, cytoplasmic fraction. Serological studies of humoral responses to high-risk
papillomavirus types have shown that bacterially ex-
pressed proteins or peptides corresponding to HPV pro-
tem selfassemble into VLPs that contain L1 and L2. Previ- teins do not allow discrimination between closely related
ous attempts to produce HPV VLPs in mammalian cells HPV types. Several antibody reactive epitopes in the ma-
have met with mixed success. Whereas HPV1 L1 pro- jor capsid protein L1 that are exposed on disrupted viri-
duced in BSC-1 cells assembled into VLPs of expected
morphology (Hagensee et al., 1993), HPV16 VLPs pro-
duced in CV-1 cells, using a vaccinia virus-based expres-
sion system, appeared incorrectly assembled and had a
diameter between 35 and 40 nm as opposed to 55 nm
as expected (Zhou et al., 1991). This is in contrast to the
VLPs produced here, which have correct morphology and
the expected size, most likely because the L1 gene from
the reference strain of HPV16 (Seedorf et al., 1985) was
used in the previous attempts (Zhou et al., 1991). The
HPV16 L1 and L2 genes that we PCR-amplified were
derived from a cervical swab sample from a young, sexu-
ally active woman and is therefore likely to be derived
from a viable wild-type virus. Indeed, the L1 gene cloned
here contains aspartic acid rather than histidine at posi-
tion 202 and its product also efficiently formed VLPs.
VLPs of HPV16 have been successfully produced in
insect cells. However, the posttranslational machinery in
such cells is different from that of mammalian cells which
may have important consequences. For example, a sig-
nificant proportion of antibodies to the human immunode-
ficiency virus type 1 (HIV-1) envelope glycoprotein recog-
nized epitopes that are dependent on the mammalian
glycosylation pattern and therefore failed to react with
HIV-1 envelope glycoprotein produced from recombinant
baculovirus (Moore et al., 1990). In addition, tubular HPV-
like particles have been detected in some HPV VLP ex-
pression systems (Sasagawa et al., 1995; Volpers et al.,
1993), but such structures were not found here. There-
FIG. 4. CsCl equilibrium density gradient centrifugation of extractsfore, the VLPs produced here may be more similar to
from BHK-21 cells infected with vSFV16L1. (A) Western immunoblottingvirus capsids produced from infected cells, which may
with rabbit anti HPV16 L1 peptide antiserum on fractions from the
be an advantage if these VLPs are to be used for studies CsCl gradient. Numbers 1–10 represent various gradient fractions.
of the immune responses to HPV16 infection, virus as- Molecular weight markers are shown on the left. (B) Graph showing
density of the fractions analyzed by Western immunoblotting in (A).sembly, or virus-receptor interactions. A recent report
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FIG. 5. Electron micrographs of purified HPV16 VLPs. Particles were purified from cells infected with vSFV16L1 (A) or with vSFV16L1 and vSFV16L2
(B). The diameter of VLPs is 50 –55 nm. Two different magnifications are shown from each preparation.
ons are shared by most PVs (Dillner et al., 1991). Since cells can identify a larger number of the HPV16-infected
women. We estimated the yield of HPV16 L1 protein toantibody responses against baculovirus-expressed
HPV16 VLPs are detected in 59% of women with cervical 100 ng from one 35-mm cell culture plate with
vSFV16L1-infected cells. It should therefore be possibleHPV16 infection, whereas only in 6% of women with
HPV6/11 infection, demonstrating that HPV16 VLPs con- to scale up infections to obtain preparative amounts of
HPV16 VLPs that could be used as antigen in ELISAtain immunodominant epitopes eliciting type-restricted
antibodies in humans (Kirnbauer et al., 1994). It is not assays.
VLPs also have many properties needed for a preven-known if the 40% of HPV16-infected women that did not
show seroreactivity to the VLPs are truly seronegative or tative HPV vaccine. Vaccines for human use must for
safety reasons not contain the oncogenic genes of theif the VLPs used may have lacked some conformationally
dependent epitopes. It will be of interest to test if VLP viral DNA. The majority of human sera reactive to intact
HPV11 capsids neutralize HPV11 infectivity (ChristensenELISA based on HPV16 VLPs produced in mammalian
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and bovine, canine, and avian papillomaviruses. J. Virol. 65, 6862–
6871.
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